44 filings
Page 2 of 3
8-K
y37imy h5uw2vu
23 Feb 23
IN8bio Presents Preclinical Data Showing Non-Signaling CAR Platform Targets Cancer Cells While Preserving Healthy Tissue
7:08am
8-K
rsd632gfdx7yjrv56
5 Jan 23
IN8bio Provides INB-200 Clinical Update and Outlines 2023 Pipeline Goals
7:08am
8-K
ql1xs7w
12 Dec 22
IN8bio Announces New Data at ASH Showing 100 Percent of Cohort 1 Patients Maintained Durable Complete Response in Ongoing Phase 1 Trial of INB-100
7:53am
8-K
ws0k1462nbbm6vkhgq
8 Dec 22
IN8bio Announces FDA Clearance to Initiate a Phase 2 Clinical Trial of INB-400 Gamma-Delta T Cells for Glioblastoma
7:10am
8-K/A
m2tev9a
6 Dec 22
IN8bio Reports Third Quarter 2022 Financial Results and Highlights Recent Company Progress
4:06pm
8-K
5fgnvpe
10 Nov 22
IN8bio Reports Second Quarter 2022 Financial Results and Provides Corporate Update
8:03am
8-K
w9hg ztq2g8bpoar1
13 Oct 22
Regulation FD Disclosure
8:44am
8-K
29rdcdh
19 Aug 22
IN8bio Announces Closing of Exercise Option to Purchase Additional Shares in Public Offering
4:06pm
8-K
k5ob vu18
16 Aug 22
IN8bio Announces Pricing of
5:03pm
8-K
fucb htz39
12 Aug 22
IN8bio Reports Second Quarter 2022 Financial Results and Provides Corporate Update
4:18pm
8-K
1a567jpk8crd154844i
8 Aug 22
Results of Operations and Financial Condition
6:55am
8-K
rlg14oh3uce jlwq2u
27 Jul 22
Other Events
8:00am
8-K
qpvxjnrjbkp5jrj
8 Jun 22
Regulation FD Disclosure
9:08am
8-K
zx8chidni1irl
2 Jun 22
Submission of Matters to a Vote of Security Holders
4:16pm
8-K
4od7bg24uy
12 May 22
IN8bio Reports First Quarter 2022 Financial Results and Provides Corporate Update
8:19am
8-K
xcpb7edwpk9 ku6tdjm1
28 Mar 22
Other Events
8:10am
8-K
3ct5 daem
17 Mar 22
IN8bio Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides Corporate Update
4:23pm
8-K
t45gej7gi83rx
10 Jan 22
Regulation FD Disclosure
9:04am
8-K
eqy04sk
16 Dec 21
IN8bio Provides Update from the Ongoing Phase 1 Clinical Trial of its
8:56am
8-K
nyi 8caay
9 Dec 21
Departure of Directors or Certain Officers
4:40pm